The clinical, social and economic value of vaccination varies both with time and by population group
In most wealthy and in many middle income countries, capsular group B Neisseria meningitidis (MenB) remains an important cause of invasive disease, particularly in the era of control of other major bacterial pathogens, such as MenC, Haemophilus influenzae type b, and vaccine-type pneumococcus. Two new MenB vaccines1,2 (now licensed in many countries) provide the potential for a comprehensive approach to controlling these invasive bacterial pathogens. However, decisions about vaccination at the population level are complex when there are low rates of disease: cost-effectiveness is a particularly important factor.3
Publication of your online response is subject to the Medical Journal of Australia's editorial discretion. You will be notified by email within five working days should your response be accepted.